<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Eosinophilic fasciitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Eosinophilic fasciitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Eosinophilic fasciitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Simon M Helfgott, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Varga, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Eosinophilic fasciitis (EF) is an uncommon disorder of unknown etiology and poorly understood pathogenesis [<a href="#rid1">1</a>]. EF is characterized in its early phase by limb or trunk erythema and nonpitting edema and later by collagenous thickening of the subcutaneous fascia. Eosinophilia is a prominent laboratory finding in the early phase, although not always present in active early cases and less prominent in later stages [<a href="#rid2">2</a>].</p><p>This topic will review the clinical manifestations, pathology, diagnosis, differential diagnosis, and treatment of EF. The approach to the patient with eosinophilia, and other major causes of eosinophilia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a> and  <a class="medical medical_review" href="/z/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia"</a>.)</p><p class="headingAnchor" id="H3161796482"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The etiology of eosinophilic fasciitis (EF) is unknown. The following have been suggested as possible triggers or factors associated with EF [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Strenuous exercise [<a href="#rid1">1</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Initiation of hemodialysis [<a href="#rid4">4</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Infection with <em>Borrelia burgdorferi</em> [<a href="#rid5">5-7</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>Physical factors such as radiation therapy and burns</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic graft-versus-host disease (GVHD)</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to certain medications including statins, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a>, subcutaneous heparin, and immune checkpoint inhibitor therapy (eg, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>) [<a href="#rid8">8-10</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune diseases including thyroid disease [<a href="#rid11">11-15</a>], primary biliary cirrhosis, systemic lupus erythematosus, and Sjögren's disease</p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic disorders (see <a class="local">'Association with hematologic disorders'</a> below)</p><p></p><p>However, most cases of EF are not associated with these factors and are considered idiopathic.</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Eosinophilic fasciitis (EF) is characterized by symmetrical bilateral induration of the skin and deeper perimuscular fascial planes [<a href="#rid16">16,17</a>]. The onset is typically acute, when findings include erythema, swelling, and induration of the extremities that is accompanied by peripheral blood eosinophilia [<a href="#rid18">18</a>]. A subacute course may also occur. The thickening and hide-bound quality of the affected skin is similar to that seen with the scleroderma-spectrum disorders.</p><p class="headingAnchor" id="H2655476694"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>The following features can be observed in patients with EF:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin involvement</strong> – Nearly all patients with EF have clinically apparent symmetrical bilateral skin involvement, although unilateral skin disease can occur. There is a temporal evolution of skin findings. Initially, there may be marked, non-pitting edema of the skin. With progression of the disease, the swelling resolves and is replaced by symmetrical induration with puckering that gives the skin the texture of orange peel (peau d'orange). Following onset of symptoms, there may be involvement of additional areas over the course of weeks. While the initial edematous phase may be indistinguishable from early sclerodermatous skin changes, the irregular, woody, peau d'orange texture of established EF is distinct from the smooth, shiny skin surface seen in patients with systemic sclerosis (<a class="graphic graphic_picture graphicRef65829" href="/z/d/graphic/65829.html" rel="external">picture 1</a>). Skin involvement most commonly occurs on the extremities, neck, and trunk. Scleroderma of the fingers (sclerodactyly), the hallmark of systemic sclerosis, is absent in EF. Moreover, the skin of the hands and feet is generally spared.</p><p></p><p class="bulletIndent1">Elevation of an affected limb, which reduces the distending venous pressure, causes visible indentation along the course of the superficial veins (<a class="graphic graphic_picture graphicRef98466" href="/z/d/graphic/98466.html" rel="external">picture 2</a>). This physical finding, referred to as the "groove sign," is probably due to the relative sparing of the epidermis and superficial dermis by the fibrotic process coupled with the relative immobility of the connective tissue around the remainder of the veins. Thus, the superficial layers of skin can bow inward as the peripheral venous pressure falls.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arthritis</strong> – Inflammatory arthritis occurs in a substantial minority of patients with EF. In one study of 52 patients with EF, 40 percent had arthritis [<a href="#rid19">19</a>]. The arthritis tends to involve joints in the areas adjacent to fasciitis. Limited joint mobility may be the result of thickening and loss of pliability of overlying skin and fascia. Joint contractures may develop, sometimes occurring in the absence of typical skin involvement [<a href="#rid20">20</a>]. In the series of 52 patients cited earlier [<a href="#rid19">19</a>], 56 percent had flexion contractures of the joints.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myalgias and myositis</strong> – Muscle pain and muscle weakness are common symptoms in EF [<a href="#rid21">21</a>]. Deep skin and fascial involvement merging into perimyositis may occur. However, inflammatory myositis is uncommon.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathies</strong> – Cranial and peripheral neuropathies occur more often than would be expected by chance. Carpal tunnel syndrome has been a commonly described peripheral neuropathy in association with EF [<a href="#rid19">19,22</a>], occurring in 12 of 52 patients (23 percent) in one series [<a href="#rid19">19</a>]. In one case, electromyography (EMG) and nerve conduction studies of the lower extremities attributed a peripheral neuropathy to mononeuritis multiplex [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visceral involvement</strong> – Visceral involvement is rarely present in patients with EF [<a href="#rid19">19</a>]. Occasional cases of pleural effusions [<a href="#rid24">24</a>], pericarditis [<a href="#rid25">25</a>], and renal involvement [<a href="#rid26">26</a>] have been described.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>The majority of patients with EF have a peripheral blood eosinophilia early in the disease [<a href="#rid19">19</a>]. Peripheral eosinophilia is transient and does not correlate with disease severity. Over 50 percent of patients have elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), as well as a polyclonal hypergammaglobulinemia [<a href="#rid19">19,27</a>]. Serum antinuclear antibodies have not been reported to be present in EF with any consistency [<a href="#rid17">17</a>]. Serum levels of creatine kinase (CK) are typically normal, even in patients with myalgia.</p><p class="headingAnchor" id="H2114086153"><span class="h2">Association with hematologic disorders</span><span class="headingEndMark"> — </span>Hematologic disorders can be seen associated with EF in up to 10 percent of patients and can be the presenting manifestation [<a href="#rid19">19</a>]. Hematologic abnormalities that have been described in association with EF include [<a href="#rid19">19,28-38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Aplastic anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Acquired amegakaryocytic thrombocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Myeloproliferative disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Myelodysplastic syndromes</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocytic and eosinophilic leukemia</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple myeloma</p><p class="bulletIndent1"><span class="glyph">●</span>Paroxysmal nocturnal hemoglobinuria</p><p></p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3047858240"><span class="h2">Overall approach</span><span class="headingEndMark"> — </span>The diagnosis of eosinophilic fasciitis (EF) is suspected in patients presenting with erythema, swelling, and induration of the extremities that is accompanied by peripheral eosinophilia. Skin changes typically spare the fingers, hands, and feet, and evidence of systemic involvement is usually absent. The absence of a history of Raynaud phenomenon helps distinguish EF from systemic sclerosis. In most cases, the diagnosis of EF is confirmed with a full thickness skin-to-muscle biopsy. We obtain magnetic resonance imaging (MRI) of the affected area when the biopsy is nondiagnostic or cannot be obtained. In atypical cases (eg, fasciitis without clinically evident skin changes), MRI may also be useful for guiding the location of a biopsy. In light of the association of EF with hematologic disorders, we also carefully review the complete blood count to determine whether further hematologic investigations are warranted.</p><p class="headingAnchor" id="H15"><span class="h3">Biopsy</span><span class="headingEndMark"> — </span>Skin biopsy for EF requires an elliptical full thickness incisional biopsy of skin and subcutaneous tissues down to the muscle surface. Although there is no pathognomonic finding of EF on biopsy, the finding of compatible pathologic changes in the deep dermis and fascia at any point in the disease course is helpful in ruling out systemic sclerosis and other scleroderma-like disorders.</p><p>Early in the course of the disease, the deep fascia and lower subcutis are edematous and infiltrated with lymphocytes, plasma cells, histiocytes, and eosinophils; these features are generally associated with peripheral eosinophilia. Eosinophil infiltrates are present in the majority of patients but may also be absent [<a href="#rid8">8</a>]. The fascia becomes thickened and sclerotic as EF progresses, with disappearance of inflammatory cell infiltrates (<a class="graphic graphic_picture graphicRef68370" href="/z/d/graphic/68370.html" rel="external">picture 3</a>) [<a href="#rid39">39</a>].</p><p>Infiltrating eosinophils in the fascia degranulate locally, resulting in release and tissue accumulation of cellular proteins such as cationic granule proteins that have toxic and potentially fibrogenic properties (<a class="graphic graphic_picture graphicRef76113" href="/z/d/graphic/76113.html" rel="external">picture 4</a>) [<a href="#rid40">40</a>]. Mast cells and their degranulation product, histamine, have been found in affected tissue as well, and elevated circulating levels of histamine have been noted in some patients with EF [<a href="#rid41">41</a>].</p><p>Histologic abnormalities are also frequently found in the subjacent muscle. Thickening and inflammation of varying severity occurs in the epimysium, in the perimysium, in the endomysium, and, to a lesser degree, even within muscle fibers. This was illustrated in a study of 15 patients with EF who had muscle biopsies that were compared with biopsies from 94 postmortem controls [<a href="#rid42">42</a>]. All 15 EF muscle biopsies showed some degree of inflammation of the epi-, peri-, or endomysium or of muscle fibers. With routine histologic studies, the inflammation in EF in or around muscles could not be distinguished from that seen in other idiopathic inflammatory myopathies, such as polymyositis or dermatomyositis.</p><p class="headingAnchor" id="H359650145"><span class="h3">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Findings on MRI are helpful to confirm fascial inflammation [<a href="#rid43">43-45</a>]. Increased T2 signal in the subcutaneous and deep fascia and enhancement of these structures on fat-suppressed T1 images after gadolinium administration have been noted [<a href="#rid20">20,43-48</a>]. If performing MRI is not possible or is contraindicated, other imaging modalities can be used. These include ultrasound and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) [<a href="#rid49">49,50</a>]. We prefer ultrasound because of its ease of administration and lower cost compared with nuclear medicine testing.</p><p class="headingAnchor" id="H16"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A variety of other disorders including localized and systemic sclerosis as well as exposures to certain chemicals (tryptophan- or 5-hydroxytryptophan-containing products) should be considered in the differential diagnosis of eosinophilic fasciitis (EF).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized scleroderma</strong> – Localized forms of scleroderma include morphea, linear, and diffuse or pansclerotic scleroderma. Unlike EF, localized forms of scleroderma generally have a slowly progressive course and are not associated with significant eosinophilia. (See  <a class="medical medical_review" href="/z/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic sclerosis</strong> – Skin changes associated with systemic sclerosis may be difficult to distinguish from those of EF. The absence of the Raynaud phenomenon favors a diagnosis of EF, since the overwhelming majority of patients with limited and diffuse cutaneous forms of systemic sclerosis have or develop Raynaud phenomenon at or near the time of the earliest skin changes. Nailfold capillaries are typically normal in EF, while dilated capillary loops, microhemorrhages, and avascular areas observed by capillaroscopy are seen in systemic sclerosis [<a href="#rid51">51</a>]. Unlike systemic sclerosis, digital tip pitting is absent and the fingers, feet, and face are spared in EF. Internal organ involvement (eg, pulmonary fibrosis, pulmonary hypertension, renal crisis) is frequent in systemic sclerosis but typically absent in EF. In contrast to systemic sclerosis, EF is only rarely associated with serum antinuclear antibodies or systemic sclerosis-specific autoantibodies. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scleroderma-like disorders</strong> – Skin thickening and decreased pliability similar to that seen with scleroderma and EF may occur in the following scleroderma-like disorders. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Causes of scleroderma-like skin changes'</a>.):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nephrogenic systemic fibrosis</strong> – Among patients with advanced renal failure (dialysis-dependent or estimated glomerular filtration rate less than 15 mL/min), the administration of gadolinium may be associated with nephrogenic systemic fibrosis (previously called nephrogenic fibrosing dermopathy). The clinical manifestations of this novel syndrome resemble EF but are distinguished by frequent involvement of the hands and feet and the absence of eosinophilia and eosinophilic tissue infiltration. (See  <a class="medical medical_review" href="/z/d/html/1955.html" rel="external">"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Scleromyxedema</strong> – Scleromyxedema is an idiopathic disorder that may occur alone or in association with malignancies. Skin thickening is due to the deposition of an amorphous mucinous material in the dermis [<a href="#rid52">52</a>]. The presence of waxy, yellow-red papules and a serum monoclonal gammopathy are characteristic features. (See  <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy", section on 'Scleromyxedema'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Scleredema</strong> – Diffuse skin induration without serum autoantibodies or evidence of inflammation on skin biopsy is typical of scleredema. These skin changes may occur in patients with diabetes, typically those with longstanding insulin-treated disease. Scleredema may also occur in the absence of associated diabetes mellitus. Associated plasma cell disorder and a monoclonal gammopathy have been described. (See  <a class="medical medical_review" href="/z/d/html/89274.html" rel="external">"Scleredema"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilia and skin thickening</strong> – When significant peripheral blood eosinophilia and skin or fascial thickening are both present, the differential diagnosis is more limited; among the diseases to be considered are the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eosinophilia myalgia syndrome</strong> – The pathology of skin and subcutaneous tissue in eosinophilia-myalgia syndrome (EMS), a condition associated with use of L-tryptophan supplements, cannot be differentiated from EF. Most cases of EMS resulted from exposure to a contaminant of the dietary supplement L-tryptophan used most commonly to treat insomnia. The illness occurred in the United States and other countries in an epidemic form in 1989, and subsequent sporadic cases have been rare [<a href="#rid53">53</a>]. A related supplement, 5-hydroxytryptophan, has also been suggested as a cause. Myalgia, often severe, is seen in EMS and is one of the classification criteria, whereas myalgia is infrequent and mild in patients with EF. Nonpitting edema of the extremities that evolves into induration with a peau d'orange appearance in EMS is similar to that seen with EF [<a href="#rid18">18</a>]. Visceral involvement, such as pneumonitis and neuropathy, may occur in patients with EMS, whereas these are uncommon in EF. (See  <a class="medical medical_review" href="/z/d/html/7557.html" rel="external">"Risk factors for and possible causes of systemic sclerosis (scleroderma)", section on 'L-tryptophan'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Toxic oil syndrome</strong> – Adulterated rapeseed oil was associated with an epidemic outbreak in the 1980s in Spain. The illness was characterized by symptoms of dyspnea, myalgia, and arthralgia; physical findings of limb edema, chronic scleroderma-like skin changes, livedo reticularis, neuropathy, and joint contractures [<a href="#rid54">54-56</a>]. Other clinical features included pulmonary infiltrates, prominent eosinophilia, and elevation of serum creatine kinase (CK) [<a href="#rid54">54-56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft-versus-host disease</strong> – Skin induration and fibrosis are common manifestations of chronic graft-versus-host disease (GVHD). Both morphea-like, localized induration and eosinophilic fasciitis have been described [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/13760.html" rel="external">"Cutaneous manifestations of graft-versus-host disease (GVHD)", section on 'Sclerotic manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Systemic glucocorticoids are the mainstay of treatment of eosinophilic fasciitis (EF). Patients who do not respond to initial therapy with glucocorticoids or who have relapses of skin involvement require additional therapy. Patients with an associated hematologic disorder should be evaluated and treated for the underlying disease.</p><p class="headingAnchor" id="H2500764324"><span class="h2">Initial therapy</span><span class="headingEndMark"> — </span>No randomized trials have evaluated therapies for EF, and the best approach to treatment remains unclear. Our approach is to treat initially with systemic glucocorticoids, usually starting at doses equivalent to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg per day [<a href="#rid19">19,58,59</a>]. There is often a rapid resolution of the peripheral blood eosinophilia and normalization of the erythrocyte sedimentation rate (ESR). Doses are slowly reduced as the affected skin softens, which can take from weeks to months, and generally lags behind the resolution of eosinophilia. If symptoms and signs of EF do not improve and/or eosinophilia persists, higher doses of glucocorticoids may be necessary.</p><p>All patients treated with high-dose glucocorticoids are at risk for glucocorticoid-induced osteoporosis. Thus, patients initiating treatment courses of EF are potential candidates for antiresorptive therapy to prevent bone loss. The prevention and treatment of glucocorticoid-induced osteoporosis are discussed separately (see  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>). Also, patients on high-dose glucocorticoid therapy are at increased risk for opportunistic infection. Prophylaxis against <em>Pneumocystic jirovecii</em> is thus often indicated for patients treated with high-dose glucocorticoids and/or other immunosuppressive agents. (See  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p class="headingAnchor" id="H2392072307"><span class="h2">Treatment of relapsed or refractory disease</span><span class="headingEndMark"> — </span>Relapses of EF may occur, and many patients do not respond to glucocorticoids [<a href="#rid19">19,58,60</a>]; thus, other immunosuppressive or immunomodulatory agents are required to obtain a therapeutic response and/or as glucocorticoid-sparing agents.</p><p>Superior response rates were reported in combining a glucocorticoid medication with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> 15 to 25 mg/week [<a href="#rid61">61</a>]. In a retrospective review of 89 patients with EF from a single institution, from 1997 to 2016, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> treatment was supplemented with methotrexate in 79 percent of cases, with <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> in 45 percent of cases, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil in 18 percent, and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> in 8 percent. No single immunosuppressant agent was associated with a superior response during treatment. Complete response rate was 60 percent at three years.</p><p>In patients with no evidence of a satisfactory response to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at doses of up to 1.5 mg/kg/day given for three months, we use low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (15 to 25 mg once weekly), following the dosing regimen employed in rheumatoid arthritis. The usual duration of therapy once remission is achieved is four to six months, depending upon the clinical response. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis"</a>.)</p><p>Alternatives to <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> include <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> or <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, although there are limited data supporting the use of either agent [<a href="#rid19">19,62</a>]. A two- to four-month trial of one or the other of these agents should be sufficient to assess the clinical response.</p><p class="headingAnchor" id="H2100910058"><span class="h2">Other interventions</span><span class="headingEndMark"> — </span>The successful use of other therapies is largely based on anecdotal reports and case series. These interventions include <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> [<a href="#rid63">63</a>], <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> [<a href="#rid64">64</a>], <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> A, ultraviolet A (UVA) 1 phototherapy, psoralen plus UVA (PUVA) photochemotherapy, and antithymocyte globulin [<a href="#rid19">19,27,59,65-71</a>]. Some patients with refractory disease have been reported to respond to treatment with anti-interleukin (IL) 5 antibody <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a> [<a href="#rid72">72</a>]. Consideration for these agents should be reserved for patients with refractory disease that is unresponsive to more traditional second- and third-line therapies. Physical therapy is generally useful for preventing the development of joint contractures.</p><p>Surgical release of joint contractures in combination with glucocorticoid therapy has been used [<a href="#rid73">73</a>]. Others have resorted to surgical fasciectomy in patients resistant to glucocorticoids [<a href="#rid74">74</a>]. Surgical release may also be necessary for some patients with chronic carpal tunnel syndrome that does not respond to glucocorticoids [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H827334950"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The majority of patients (75 percent) respond to glucocorticoid therapy, and approximately half of all patients can achieve remission with glucocorticoid therapy. Patients seen in the edematous phase generally demonstrate a prompt resolution of the edema with glucocorticoid treatment. The presence of peau d'orange is associated with an incomplete response to therapy [<a href="#rid75">75</a>].</p><p>Skin disease affecting the trunk is also associated with treatment resistance (hazard ratio 1.87, 95% CI 1.06-3.31) [<a href="#rid75">75</a>]. Patients with an incomplete response to therapy may develop chronic skin thickening and localized soft tissue contractures.</p><p class="headingAnchor" id="H4100649458"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120094.html" rel="external">"Society guideline links: Eosinophilic fasciitis"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Eosinophilic fasciitis (EF) is an uncommon disorder of unknown etiology and poorly understood pathogenesis. Exposure to certain medications, including immune checkpoint inhibitors, has been associated with EF onset. The onset is typically acute, and findings include erythema, swelling, and induration of the extremities that is accompanied by a peripheral blood eosinophilia. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms and signs</strong> – The thickening and hide-bound quality of the affected skin is somewhat similar to that seen with the scleroderma-spectrum disorders; however, sclerodactyly, the hallmark of systemic sclerosis, is absent in EF. Moreover, the skin of the hands and feet is generally spared. Elevation of an affected limb, which reduces the distending venous pressure, causes visible indentation (the groove sign) along the course of the superficial veins (<a class="graphic graphic_picture graphicRef98466" href="/z/d/graphic/98466.html" rel="external">picture 2</a>). (See <a class="local">'Symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – The majority of EF patients have a peripheral blood eosinophilia. Peripheral eosinophilia is transient and does not correlate with disease severity. Over 50 percent of patients have an elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as well as a polyclonal hypergammaglobulinemia. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Association with hematologic disorders</strong> – Hematologic disorders can be associated with EF in up to 10 percent of patients and can be the presenting manifestation. (See <a class="local">'Association with hematologic disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of EF is suspected in patients presenting with erythema, swelling, and induration of the extremities that is accompanied by peripheral eosinophilia. Skin changes typically spare the hands and feet, and evidence of systemic involvement is usually absent. In most cases, the diagnosis of EF is confirmed with a full skin-to-muscle biopsy. We obtain MRI of the affected area when the biopsy is nondiagnostic or cannot be obtained. In atypical cases (eg, fasciitis without skin changes), MRI may also be useful for guiding the location of a biopsy. (See <a class="local">'Overall approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis includes localized and systemic sclerosis; scleroderma-like disorders such as nephrogenic systemic fibrosis, scleromyxedema, and scleredema; eosinophilia myalgia syndrome (EMS), toxic oil syndrome; and graft-versus-host disease (GVHD). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For all patients with EF, we suggest initial management with systemic glucocorticoids, usually starting at doses equivalent to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg per day (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Doses are reduced as the affected skin softens, which can take from weeks to months. If symptoms and signs of EF do not improve and eosinophilia persists, higher doses of glucocorticoids may be necessary. Patients with an associated hematologic disorder should be treated for the underlying disease. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent therapy</strong> – In patients with no evidence of a response to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at doses of up to 1.5 mg/kg/day given for three months, we suggest treatment with low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (15 to 25 mg once weekly) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The usual duration of therapy once remission is achieved is four to six months, depending upon the clinical response. (See <a class="local">'Treatment of relapsed or refractory disease'</a> above.)</p><p></p><p class="bulletIndent2">Alternatives to <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> include <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> or <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, although there are limited data supporting the use of either agent. A two- to four-month trial of one or the other of these agents should be sufficient to assess the clinical response. (See <a class="local">'Treatment of relapsed or refractory disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other interventions</strong> – The successful use of other therapies is largely based on anecdotal reports and case series. Some of these interventions include <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> A, ultraviolet A (UVA) 1 phototherapy, psoralen plus UVA (PUVA) photochemotherapy, antithymocyte globulin, and <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>. Consideration for these agents should be reserved for patients with refractory disease that is unresponsive to more traditional second- and third-line therapies. Rarely, surgical interventions have been used in patients resistant to glucocorticoids. (See <a class="local">'Other interventions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 1975; 88:70.</a></li><li><a class="nounderline abstract_t">Falanga V, Medsger TA Jr. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J Am Acad Dermatol 1987; 17:648.</a></li><li><a class="nounderline abstract_t">Pinal-Fernandez I, Selva-O' Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 2014; 13:379.</a></li><li><a class="nounderline abstract_t">Florell SR, Egan CA, Gregory MC, et al. Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient. J Cutan Med Surg 2001; 5:33.</a></li><li><a class="nounderline abstract_t">Granter SR, Barnhill RL, Duray PH. Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection. Am J Dermatopathol 1996; 18:465.</a></li><li><a class="nounderline abstract_t">Hashimoto Y, Takahashi H, Matsuo S, et al. Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Dermatology 1996; 192:136.</a></li><li><a class="nounderline abstract_t">Mosconi S, Streit M, Brönimann M, Braathen L. Eosinophilic fasciitis (Shulman syndrome). Dermatology 2002; 205:204.</a></li><li><a class="nounderline abstract_t">Long H, Zhang G, Wang L, Lu Q. Eosinophilic Skin Diseases: A Comprehensive Review. Clin Rev Allergy Immunol 2016; 50:189.</a></li><li><a class="nounderline abstract_t">Le Tallec E, Lescoat A, Ballerie A, et al. Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus. J Thorac Oncol 2020; 15:e29.</a></li><li><a class="nounderline abstract_t">Chan KK, Magro C, Shoushtari A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist 2020; 25:140.</a></li><li><a class="nounderline abstract_t">Bachmeyer C, Monge M, Dhôte R, et al. Eosinophilic fasciitis following idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Hashimoto's disease. Dermatology 1999; 199:282.</a></li><li><a class="nounderline abstract_t">Farrell AM, Ross JS, Bunker CB. Eosinophilic fasciitis associated with autoimmune thyroid disease and myelodysplasia treated with pulsed methylprednisolone and antihistamines. Br J Dermatol 1999; 140:1185.</a></li><li><a class="nounderline abstract_t">Imren S, Tüzüner N, Yazici H. Eosinophilic fasciitis with thyroid disease. Clin Exp Rheumatol 1988; 6:96.</a></li><li><a class="nounderline abstract_t">Boiesen M, Keiding LM, Thomsen K. Eosinophilic fasciitis. Report of a case with features of other autoimmune disease. Dermatologica 1983; 167:142.</a></li><li><a class="nounderline abstract_t">Smiley AM, Husain M, Indenbaum S. Eosinophilic fasciitis in association with thyroid disease: a report of three cases. J Rheumatol 1980; 7:871.</a></li><li><a class="nounderline abstract_t">Rodnan GP, DiBartolomeo A, Medsger TA Jr. Proceedings: Eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome. Arthritis Rheum 1975; 18:525.</a></li><li><a class="nounderline abstract_t">Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin North Am 1989; 73:1157.</a></li><li><a class="nounderline abstract_t">Varga J, Griffin R, Newman JH, Jimenez SA. Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use. J Rheumatol 1991; 18:259.</a></li><li><a class="nounderline abstract_t">Lakhanpal S, Ginsburg WW, Michet CJ, et al. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988; 17:221.</a></li><li><a class="nounderline abstract_t">Huppke P, Wilken B, Brockmann K, et al. Eosinophilic fasciitis leading to painless contractures. Eur J Pediatr 2002; 161:528.</a></li><li><a class="nounderline abstract_t">Nassonova VA, Ivanova MM, Akhnazarova VD, et al. Eosinophilic fasciitis. Review and report of six cases. Scand J Rheumatol 1979; 8:225.</a></li><li><a class="nounderline abstract_t">Jones HR Jr, Beetham WP Jr, Silverman ML, Margles SW. Eosinophilic fasciitis and the carpal tunnel syndrome. J Neurol Neurosurg Psychiatry 1986; 49:324.</a></li><li><a class="nounderline abstract_t">Moriguchi M, Terai C, Kuroki S, et al. Eosinophilic fasciitis complicated with peripheral polyneuropathy. Intern Med 1998; 37:417.</a></li><li><a class="nounderline abstract_t">Killen JW, Swift GL, White RJ. Eosinophilic fasciitis with pulmonary and pleural involvement. Postgrad Med J 2000; 76:36.</a></li><li><a class="nounderline abstract_t">Rizzo S. Eosinophilic pleuropericarditis and fasciitis. A new case. Monaldi Arch Chest Dis 2002; 57:311.</a></li><li><a class="nounderline abstract_t">Kirschstein M, Helmchen U, Jensen R, et al. Kidney involvement in a 17-year-old boy with eosinophilic fasciitis. Clin Nephrol 1999; 52:183.</a></li><li><a class="nounderline abstract_t">Lebeaux D, Sène D. Eosinophilic fasciitis (Shulman disease). Best Pract Res Clin Rheumatol 2012; 26:449.</a></li><li><a class="nounderline abstract_t">Doyle JA, Connolly SM, Hoagland HC. Hematologic disease in scleroderma syndromes. Acta Derm Venereol 1985; 65:521.</a></li><li><a class="nounderline abstract_t">Hoffman R, Dainiak N, Sibrack L, et al. Antibody-mediated aplastic anemia and diffuse fasciitis. N Engl J Med 1979; 300:718.</a></li><li><a class="nounderline abstract_t">Littlejohn GO, Keystone EC. Eosinophilic fasciitis and aplastic anaemia. J Rheumatol 1980; 7:730.</a></li><li><a class="nounderline abstract_t">Chaudhary UB, Eberwine SF, Hege KM. Acquired amegakaryocytic thrombocytopenia purpura and eosinophilic fasciitis: a long relapsing and remitting course. Am J Hematol 2004; 75:146.</a></li><li><a class="nounderline abstract_t">Khanna D, Verity A, Grossman JM. Eosinophilic fasciitis with multiple myeloma: a new haematological association. Ann Rheum Dis 2002; 61:1111.</a></li><li><a class="nounderline abstract_t">Jacob SE, Lodha R, Cohen JJ, et al. Paraneoplastic eosinophilic fasciitis: a case report. Rheumatol Int 2003; 23:262.</a></li><li><a class="nounderline abstract_t">Haddad H, Sundaram S, Magro C, Gergis U. Eosinophilic fasciitis as a paraneoplastic syndrome, a case report and review of the literature. Hematol Oncol Stem Cell Ther 2014; 7:90.</a></li><li><a class="nounderline abstract_t">Ferguson JS, Bosworth J, Min T, et al. Eosinophilic fasciitis associated with hypereosinophilia, abnormal bone-marrow karyotype and inversion of chromosome 5. Clin Exp Dermatol 2014; 39:150.</a></li><li><a class="nounderline abstract_t">de Masson A, Bouaziz JD, Peffault de Latour R, et al. Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. Medicine (Baltimore) 2013; 92:69.</a></li><li><a class="nounderline abstract_t">Naschitz JE, Misselevich I, Rosner I, et al. Lymph-node-based malignant lymphoma and reactive lymphadenopathy in eosinophilic fasciitis. Am J Med Sci 1999; 318:343.</a></li><li><a class="nounderline abstract_t">Eklund KK, Anttila P, Leirisalo-Repo M. Eosinophilic fasciitis, myositis and arthritis as early manifestations of peripheral T-cell lymphoma. Scand J Rheumatol 2003; 32:376.</a></li><li><a class="nounderline abstract_t">Barnes L, Rodnan GP, Medsger TA, Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol 1979; 96:493.</a></li><li><a class="nounderline abstract_t">Fredens K, Dybdahl H, Dahl R, Baandrup U. Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage. APMIS 1988; 96:711.</a></li><li><a class="nounderline abstract_t">Falanga V, Soter NA, Kerdel FA. Increased plasma histamine level in eosinophilic fasciitis. Arch Dermatol 1989; 125:805.</a></li><li><a class="nounderline abstract_t">Huang KW, Chen XH. Pathology of eosinophilic fasciitis and its relation to polymyositis. Can J Neurol Sci 1987; 14:632.</a></li><li><a class="nounderline abstract_t">Moulton SJ, Kransdorf MJ, Ginsburg WW, et al. Eosinophilic fasciitis: spectrum of MRI findings. AJR Am J Roentgenol 2005; 184:975.</a></li><li><a class="nounderline abstract_t">De Clerck LS, Degryse HR, Wouters E, et al. Magnetic resonance imaging in the evaluation of patients with eosinophilic fasciitis. J Rheumatol 1989; 16:1270.</a></li><li><a class="nounderline abstract_t">Ronneberger M, Janka R, Schett G, Manger B. Can MRI substitute for biopsy in eosinophilic fasciitis? Ann Rheum Dis 2009; 68:1651.</a></li><li><a class="nounderline abstract_t">Nakajima H, Fujiwara S, Shinoda K, Ohsawa N. Magnetic resonance imaging and serum aldolase concentration in eosinophilic fasciitis. Intern Med 1997; 36:654.</a></li><li><a class="nounderline abstract_t">al-Shaikh A, Freeman C, Avruch L, McKendry RJ. Use of magnetic resonance imaging in diagnosing eosinophilic fasciitis. Report of two cases. Arthritis Rheum 1994; 37:1602.</a></li><li><a class="nounderline abstract_t">Baumann F, Brühlmann P, Andreisek G, et al. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol 2005; 184:169.</a></li><li><a class="nounderline abstract_t">Kim HJ, Lee SW, Kim GJ, Lee JH. Usefulness of FDG PET/CT in the diagnosis of eosinophilic fasciitis. Clin Nucl Med 2014; 39:801.</a></li><li><a class="nounderline abstract_t">Kissin EY, Garg A, Grayson PC, et al. Ultrasound assessment of subcutaneous compressibility: a potential adjunctive diagnostic tool in eosinophilic fasciitis. J Clin Rheumatol 2013; 19:382.</a></li><li><a class="nounderline abstract_t">Herson S, Brechignac S, Piette JC, et al. Capillary microscopy during eosinophilic fasciitis in 15 patients: distinction from systemic scleroderma. Am J Med 1990; 88:598.</a></li><li><a class="nounderline abstract_t">Mori Y, Kahari VM, Varga J. Scleroderma-like cutaneous syndromes. Curr Rheumatol Rep 2002; 4:113.</a></li><li><a class="nounderline abstract_t">Allen JA, Peterson A, Sufit R, et al. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum 2011; 63:3633.</a></li><li><a class="nounderline abstract_t">Alonso-Ruiz A, Zea-Mendoza AC, Salazar-Vallinas JM, et al. Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma. Semin Arthritis Rheum 1986; 15:200.</a></li><li><a class="nounderline abstract_t">Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1995; 7:560.</a></li><li><a class="nounderline abstract_t">Posada de la Paz M, Philen RM, Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 2001; 23:231.</a></li><li><a class="nounderline abstract_t">Schaffer JV, McNiff JM, Seropian S, et al. Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol 2005; 53:591.</a></li><li><a class="nounderline abstract_t">Lebeaux D, Francès C, Barete S, et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford) 2012; 51:557.</a></li><li><a class="nounderline abstract_t">Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol 2008; 47:29.</a></li><li><a class="nounderline abstract_t">Endo Y, Tamura A, Matsushima Y, et al. Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome. Clin Rheumatol 2007; 26:1445.</a></li><li><a class="nounderline abstract_t">Mango RL, Bugdayli K, Crowson CS, et al. Baseline characteristics and long-term outcomes of eosinophilic fasciitis in 89 patients seen at a single center over 20 years. Int J Rheum Dis 2020; 23:233.</a></li><li><a class="nounderline abstract_t">Tkachenko E, Steuer AB, Lo K, et al. Mycophenolate Mofetil for Eosinophilic Fasciitis: A Retrospective Analysis From 3 Tertiary Care Centers. JAMA Dermatol 2020; 156:595.</a></li><li><a class="nounderline abstract_t">Vílchez-Oya F, Sánchez-Schmidt JM, Agustí A, Pros A. The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review. Clin Rheumatol 2020; 39:1693.</a></li><li><a class="nounderline abstract_t">Sehgal R, Ernste FC, Eckloff S. Successful Treatment With Baricitinib in a Patient With Refractory Eosinophilic Fasciitis. J Rheumatol 2021; 48:948.</a></li><li><a class="nounderline abstract_t">Schiener R, Behrens-Williams SC, Gottlöber P, et al. Eosinophilic fasciitis treated with psoralen-ultraviolet A bath photochemotherapy. Br J Dermatol 2000; 142:804.</a></li><li><a class="nounderline abstract_t">Pimenta S, Bernardes M, Bernardo A, et al. Intravenous immune globulins to treat eosinophilic fasciitis: a case report. Joint Bone Spine 2009; 76:572.</a></li><li><a class="nounderline abstract_t">Bonnotte B, Chauffert B, Caillot D, et al. Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis. Br J Rheumatol 1998; 37:1358.</a></li><li><a class="nounderline abstract_t">Caspi D, Fishel R, Varon M, et al. Multisystem presentation of eosinophilic fasciitis. Rheumatol Rehabil 1982; 21:218.</a></li><li><a class="nounderline abstract_t">Jones AC, Doherty M. Eosinophilic fasciitis with late onset arthritis responsive to sulfasalazine. J Rheumatol 1993; 20:750.</a></li><li><a class="nounderline abstract_t">Khanna D, Agrawal H, Clements PJ. Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford) 2010; 49:1184.</a></li><li><a class="nounderline abstract_t">Scheinberg M, Hamerschlak N, Kutner JM, et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 2006; 24:65.</a></li><li><a class="nounderline abstract_t">Mortezavi M, Barrett M, Edrissian M. Successful treatment of refractory eosinophilic fasciitis with reslizumab. JAAD Case Rep 2020; 6:951.</a></li><li><a class="nounderline abstract_t">Suzuki G, Itoh Y, Horiuchi Y. Surgical management of eosinophilic fasciitis of the upper extremity. J Hand Surg Br 1997; 22:405.</a></li><li><a class="nounderline abstract_t">Neumeister MW, Robertson GA. Therapeutic fasciectomy for eosinophilic fasciitis. Ann Plast Surg 1998; 41:208.</a></li><li><a class="nounderline abstract_t">Zuelgaray E, Chevret S, Jachiet M, et al. Trunk involvement and peau d'orange aspect are poor prognostic factors in eosinophilic fasciitis (Shulman disease): A multicenter retrospective study of 119 patients. J Am Acad Dermatol 2023; 88:160.</a></li></ol></div><div id="topicVersionRevision">Topic 7547 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1224441" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diffuse fasciitis with eosinophilia: a new syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3668010" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424187" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis and classification of eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11281432" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8902092" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8829496" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218249" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Eosinophilic fasciitis (Shulman syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25876839" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Eosinophilic Skin Diseases: A Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32127188" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043775" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10592421" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Eosinophilic fasciitis following idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Hashimoto's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354391" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Eosinophilic fasciitis associated with autoimmune thyroid disease and myelodysplasia treated with pulsed methylprednisolone and antihistamines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3396254" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Eosinophilic fasciitis with thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6628811" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Eosinophilic fasciitis. Report of a case with features of other autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7205825" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Eosinophilic fasciitis in association with thyroid disease: a report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1191357" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Proceedings: Eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2671538" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2023221" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3232080" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12297898" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Eosinophilic fasciitis leading to painless contractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/534317" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Eosinophilic fasciitis. Review and report of six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3958745" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Eosinophilic fasciitis and the carpal tunnel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9630207" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Eosinophilic fasciitis complicated with peripheral polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10622780" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Eosinophilic fasciitis with pulmonary and pleural involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814048" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Eosinophilic pleuropericarditis and fasciitis. A new case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10499315" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kidney involvement in a 17-year-old boy with eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23040360" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Eosinophilic fasciitis (Shulman disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2420117" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hematologic disease in scleroderma syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/763302" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antibody-mediated aplastic anemia and diffuse fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6777494" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Eosinophilic fasciitis and aplastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978695" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acquired amegakaryocytic thrombocytopenia purpura and eosinophilic fasciitis: a long relapsing and remitting course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12429547" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Eosinophilic fasciitis with multiple myeloma: a new haematological association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12734672" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Paraneoplastic eosinophilic fasciitis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24525268" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Eosinophilic fasciitis as a paraneoplastic syndrome, a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24237445" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Eosinophilic fasciitis associated with hypereosinophilia, abnormal bone-marrow karyotype and inversion of chromosome 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429351" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555099" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Lymph-node-based malignant lymphoma and reactive lymphadenopathy in eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15080271" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Eosinophilic fasciitis, myositis and arthritis as early manifestations of peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/474708" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Eosinophilic fasciitis. A pathologic study of twenty cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3046642" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2730101" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Increased plasma histamine level in eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3690437" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pathology of eosinophilic fasciitis and its relation to polymyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728627" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Eosinophilic fasciitis: spectrum of MRI findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2491737" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Magnetic resonance imaging in the evaluation of patients with eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19748919" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Can MRI substitute for biopsy in eosinophilic fasciitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9313113" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Magnetic resonance imaging and serum aldolase concentration in eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7980670" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Use of magnetic resonance imaging in diagnosing eosinophilic fasciitis. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15615969" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : MRI for diagnosis and monitoring of patients with eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24152641" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Usefulness of FDG PET/CT in the diagnosis of eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24048117" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Ultrasound assessment of subcutaneous compressibility: a potential adjunctive diagnostic tool in eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2346160" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Capillary microscopy during eosinophilic fasciitis in 15 patients: distinction from systemic scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11890876" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Scleroderma-like cutaneous syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21702023" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3961509" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8579979" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12192735" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Toxic oil syndrome: the perspective after 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198778" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22120602" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173597" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17345001" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31811710" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Baseline characteristics and long-term outcomes of eosinophilic fasciitis in 89 patients seen at a single center over 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32236487" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mycophenolate Mofetil for Eosinophilic Fasciitis: A Retrospective Analysis From 3 Tertiary Care Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31974818" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34237007" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Successful Treatment With Baricitinib in a Patient With Refractory Eosinophilic Fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792237" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Eosinophilic fasciitis treated with psoralen-ultraviolet A bath photochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643651" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Intravenous immune globulins to treat eosinophilic fasciitis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973169" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7134742" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Multisystem presentation of eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098769" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Eosinophilic fasciitis with late onset arthritis responsive to sulfasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308119" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16539821" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32913886" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Successful treatment of refractory eosinophilic fasciitis with reslizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222928" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Surgical management of eosinophilic fasciitis of the upper extremity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9718158" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Therapeutic fasciectomy for eosinophilic fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33188872" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Trunk involvement and peau d'orange aspect are poor prognostic factors in eosinophilic fasciitis (Shulman disease): A multicenter retrospective study of 119 patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
